Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Bayer
Compass Therapeutics
Pliant Therapeutics, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Eastern Cooperative Oncology Group
NRG Oncology
Institut Cancerologie de l'Ouest
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Stanford University
AstraZeneca
Merck Sharp & Dohme LLC
Mayo Clinic
Aminex Therapeutics, Inc.
Hoffmann-La Roche
Psyence Australia Pty Ltd
ViroMissile, Inc.
Hummingbird Bioscience
Dana-Farber Cancer Institute
Kaiser Permanente
Mayo Clinic
University of Florida
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Sapience Therapeutics
MacroGenics
City of Hope Medical Center
Daiichi Sankyo
Novartis
M.D. Anderson Cancer Center
Second Life Therapeutics
Onchilles Pharma Inc
University of Southern California
Innate Pharma
Novartis
The Netherlands Cancer Institute
OncoNano Medicine, Inc.
Ohio State University Comprehensive Cancer Center